Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
Authors:
Open Access
- 1 December 2010
- journal article
- Published by Elsevier in Value in Health
- Vol. 13 (8) , 922-933
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis BValue in Health, 2010
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis BNew England Journal of Medicine, 2008
- [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTSJournal of Hepatology, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy–Naive and –Experienced Patients Coinfected with HIV‐1 and Hepatitis B VirusThe Journal of Infectious Diseases, 2004
- Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis BClinical Infectious Diseases, 2003
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993